Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 4, 1996, Pages 371-376

  Ramirez, Luis H ^a   Zhao, Zhongxin ^a   Rougier, Philippe ^a   Bognel, Caroline ^a   Dzodic, Radan ^a   Vassal, Gilles ^a   Ardouin, Patrice ^a   Gouyette, Alain ^a   Munck, Jean Nicolas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Experimental liver tumors; Intratumoral injections; Mitoxantrone; Pharmacokinetics

Indexed keywords

ALCOHOL; MITOXANTRONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEPATIC ARTERY; HISTOLOGY; INTRAARTERIAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; NONHUMAN; PRIORITY JOURNAL; RABBIT; TUMOR GROWTH; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; FEASIBILITY STUDIES; FEMALE; HEPATIC ARTERY; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRALESIONAL; LIVER NEOPLASMS, EXPERIMENTAL; MITOXANTRONE; RABBITS;

EID: 0030052813     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050399     Document Type: Article

References (32)

1. Alberts D, Young L, Mason N, Salmon S (1985) In-vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12 [Suppl 4]: 38-42
2. Alberts D, Peng Y, Leigh S, Davis T, Woodward D (1985) Disposition of mitoxantrone in cancer patients. Cancer Res 45:1879-1884
3. Andrews P, Johnson C (1989) Regional chemotherapy in an experimental model of Wilms' tumor in rats. Cancer Chemother Pharmacol 23:31-36
4. Bognel C, Degott C, Rougier P, Lasser P, Elias D, Grandjouan S, Duvillard P, Charpentier P, Prade M (1989) Etude anatomopathologique de la toxicité hépatique de la chimiothérapie intraartérielle hépatique. Gastroenterol Clin Biol 13:125-131
5. Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in a high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 53:4850-4854
6. Czejka M, Jäger W, Georgopoulos A, Schüller J (1990) Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. Eur J Drug Metab Pharmacokinet 15:219-222
7. Doria M, Shepard K, Levin B, Riddell R (1986) Liver pathology following hepatic arterial infusion chemotherapy. Cancer 58:855-861
8. Dorr R, Alberts D, Soble M (1986) Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemother Pharmacol 16:91-94
9. Garnick M, Ensminger W, Israel M (1979) A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res 39:4105-4110
10. Gordon I, Kar R, Opfell RW, and Wile AG (1987) Pharmacokinetics of hexamethylmelamine in intralipid following hepatic regional administration in rabbits. Cancer Res 47:5070-5073
11. Hohn D, Stagg R, Friedman M, Hannigan J, Rayner A, Ignoffo R, Acord P, Lewis B (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7:1646-1654
12. Jones D, Patt Y, Ajani J, Abbruzyese J, Carraseo C, Charnsangavej C, Levin B, Wallace S (1993) A phase I II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer 72:2560-2563
13. Kirk Martin J, O'Connell M, Wieand H, Fitzgibbons R, Mailliard J, Rubin J, Nagorney D, Tschetter L, Krook J (1990) Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125:1022-1027
14. Livraghi T, Solbiati L (1993) Percutaneous ethanol injection in liver cancer: methods and results. Semin Interv Radiol 10:69-77
15. Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J Jr (1990) Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8:146-150
16. Markman M, Alberts D, Rubin S, Hakes T, Lewis J, Reichman B, Jones W, Curtin J, Barakat R, Brodar F, Peng Y, Pennie K, Almadrones L, Hoskins W (1993) Evidence of persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. Gynecol Oncol 48:185-188
17. Miller DL, O'Leary J, Girton M (1987) Distribution of iodized oil within the liver after hepatic arterial injection. Radiology 162:849-852
18. Munck JN, Riggi M, Rougier P, Chabot GG, Ramirez LH, Zhao Z, Bognel C, Ardouin P, Hérait P, and Gouyette A (1993) Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res 53:1550-1154
19. Nagase M, Nomura T, Nakajima T (1987) Effects of intralesional versus ip administration of cisplatin on squamous cell carcinoma of mice. Cancer Treat Rep 71:825-829
20. Nordic Gastrointestinal Tumor Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: randomized trial. J Clin Oncol 10:904-911
21. Ohanian S, Schlager S, Goodman D (1980) Analysis of the intralesional adriamycin-induced regression of primary and metastatic growth of line-10 guinea-pig hepatoma. Cancer Immunol Immunother 8:179-187
22. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson R, Valone F, Labianca R, Doroshow J, Petrelli N (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896-903
23. Richard B, Fabre G, Fabre I, Cano JP (1989) Excretion and metabolism of mitoxantrone in rabbits. Cancer Res 49:833-837
24. Rougier P, Laplanche A, Huguier M, Hay J, Ollivier J, Escat J, Salmon R, Julien M, Roullet-Audy J, Gallot D, Gouzi J, Pailler J, Elisa D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P (1992) Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long term results of a prespective randomized trial. J Clin Oncol 7:1112-1118
25. Shepherd F, Evans W, Blackstein M, Fine S, Heathcote J, Langer B, Taylor B, Habal F, Kutas G, Pritchard K, Kuruvilla P (1987) Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol 5:635-640
26. Shima S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y, Hata Y, Niwa Y, Shiratori Y, Terano A, Sugimoto T (1991) Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer 68: 1524-1530
27. Stewart D, Green R, Mikhael N, Montpetit V, Thibault M, Maroun J (1986) Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 70: 1255-1261
28. Van Belle S, M Planque de, Smith I, Oosterom A van, Schoemaker T, Deneve W, McVie J (1986) Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 18:27-32
29. Vilana R, Bruix J, Bru C, Ayuso C, Solé M, Rodés J (1992) Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 16:353-357
30. Von Hoff D, Coltman C, Forseth B (1981) Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41:1853-1855
31. Von Hoff D, Clark G, Weiss G, Marshall M, Buchok J, Knight W, LeMaistre C (1986) Use of in-vitro dose response effects to select antincoplastics for high-dose or regional administration regimens. J Clin Oncol 4:1827-1834
32. Zamboglou N, Wurm R, Pape H, Schnabel T, Kuhn F, Streffer C, Schmitt G (1991) Simultaneous radiotherapy and intratumoral instillation of mitoxantrone in locoregional recurrence of head and neck carcinoma. Reg Cancer Treat 4:79-84